A correct treatment needs to be chosen.
Extrapulmonary small-cell neuroendocrine carcinomas account for 2.5%-5% of all small-cell neuroendocrine carcinomas [1] .
Neuroendocrine small cell carcinoma with features indistinguishable from pulmonary small cell carcinoma can occur in a variety of extrapulmonary sites. These tumors have been reported in the breast, larynx, trachea, stomach, small intestine, bladder prostate, cervix, ovary and many other organs and tissues [2] [3] [4] [5] .
Contrary to pulmonary small cell carcinomas, extra pulmonary tumors of this type are very uncommon. Reports also suggest that clinical course of extrapulmonary SCNC is as aggressive as its pulmonary counterpart [6, 7] .
Since its first description by Wade et al. in 1983, we were able to find only 35 recorded cases in literature (Table I) [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] .
Case report
A 53 year old female patient was admitted to the Cluj-Napoca Institute of Oncology with a palpable mass in her right breast for specialty treatment.
On examination the right breast showed a mass of about 12 cm in diameter in the lower-inner and intern quadrants. She had a 3 cm ipsilateral axillary lymphadenopathy. The left breast examination and other clinical examinations were within normal limits.
Mammography and echography revealed suspicious characteristics in the nodule ( Figures 1&2) . A core biopsy revealed a solid small-cell neuroendocrine carcinoma, G III with negative estrogen and progesterone receptors. IHC: CK AE1/AE3 pozitive, CD56 pozitive, TTF1 negative, chromogranin and synaptophysin negative.
CT/MRI scans of the lung, abdomen and bone were normal.
Confirming the breast as an origin of neuroendocrine tumor represents a challenge. The diagnosis is mainly dependent on the exclusion of other extramammary organs based on clinical, radiological, pathological and IHC data.
In conclusion Small-cell neuroendocrine breast cancer -T4bN2M0.
The patient underwent neo-adjuvant chemotherapy, 4 cycles: Farmorubicin 100 mg/mp DT = 165 mg; Ciclofosfamida 600 mg/mp DT = 980 mg and 4 cycles: Taxotere 75 mg/mp DT = 125 mg.
Partial result was achieved after neo-adjuvant therapy, the tumor being reduced to 5 cm in diameter. Again the CT/MRI scans were normal.
Subsequently the patient underwent a right radical mastectomy with axillary lymph node resection. Macroscopically, the tumor was 4-5 cm in maximum diameter. Widespread vascular invasion was present; 21 of 30 lymph nodes were metastatic.
It was decided by a multi disciplinary team that adjuvant radiotherapy was needed.
Eight months after diagnosis and one month after MRM the patient presented signs of local recurrence in the form of permeation nodules. After skin biopsy the diagnosis was confirmed.
After other investigations, CT, Rx lung and liver metastasis were discovered.
Radiotherapy was started along with hyperthermia and a new chemotherapy regime was considered.
The study was performed with the patient's consent and the approval of the hospital's ethic committee.
discussion
Small cell neuroendocrine breast cancer is generally characterized by early dissemination and a rapid, aggressive clinical course. However, the biological behaviour of mammary SmCC is still uncertain because this type of breast tumor is less frequently encountered. There are several reports, which consist largely of case reports, and these reported patients showed a relatively poor prognosis with a more advanced stage at diagnosis [28] [29] [30] . The stage of the disease at the time of diagnosis is an important determining factor of the prognosis [31] .
Conclusion
Treatment for the SmCC of the breast has not yet been established, and a consensus has yet to be reached. It is clear that more studies are needed in order to achieve an effective treatment. Unfortunately cases are very rare and their evolution very poor, making it difficult to come up with a proper treatment.
